Proinflammatory cytokine regulation of cyclic AMP‐phosphodiesterase 4 signaling in microglia in vitro and following CNS injury
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Cyclic AMP suppresses immune cell activation and inflammation. The positive feedback loop of proinflammatory cytokine production and immune activation implies that cytokines may not only be regulated by cyclic AMP but also conversely regulate cyclic AMP. This study examined the effects of tumor necrosis factor (TNF)‐α and interleukin (IL)‐1β on cyclic AMP‐phosphodiesterase (PDE) signaling in microglia in vitro and after spinal cord injury (SCI) or traumatic brain injury (TBI). TNF‐α or IL‐1β stimulation produced a profound reduction (>90%) of cyclic AMP within EOC2 microglia from 30 min that then recovered after IL‐1β but remained suppressed with TNF‐α through 24 h. Cyclic AMP was also reduced in TNF‐α‐stimulated primary microglia, albeit to a lesser extent. Accompanying TNF‐α‐induced cyclic AMP reductions, but not IL‐1β, was increased cyclic AMP‐PDE activity. The role of PDE4 activity in cyclic AMP reductions was confirmed by using Rolipram. Examination of pde4 mRNA revealed an immediate, persistent increase in pde4b with TNF‐α; IL‐1β increased all pde4 mRNAs. Immunoblotting for PDE4 showed that both cytokines increased PDE4A1, but only TNF‐α increased PDE4B2. Immunocytochemistry revealed PDE4B nuclear translocation with TNF‐α but not IL‐1β. Acutely after SCI/TBI, where cyclic AMP levels are reduced, PDE4B was localized to activated OX‐42+ microglia; PDE4B was absent in OX‐42+ cells in uninjured spinal cord/cortex or inactive microglia. Immunoblotting showed PDE4B2 up‐regulation from 24 h to 1 wk post‐SCI, the peak of microglia activation. These studies show that TNF‐α and IL‐1β differentially affect cyclic AMP‐PDE signaling in microglia. Targeting PDE4B2 may be a putative therapeutic direction for reducing microglia activation in CNS injury and neurodegenerative diseases. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weber, A., Wasiliew, P., & Kracht, M. (2010) · Science Signaling · doi:10.1126/scisignal.3105cm1 · Cited by 962 · cited 2×
“, 2006), mediating the gene expression of a number of cytokines and chemokines through the ERK, p38, JNK, and NF-jB intracellular signaling pathways that further potentiate immune cell activation, migration, phagocytosis, and antigen presentation (Weber et al., 2010).”
BackgroundDunne, A., & O'Neill, L. A. J. (2003) · Science's STKE · doi:10.1126/stke.2003.171.re3 · Cited by 711
Immune activation in brain aging and neurodegeneration: too much or too little?
Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679
Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin
Selmaj, K., Raine, C. S., Farooq, M., Norton, W. T., & Brosnan, C. F. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.5.1522 · Cited by 451
EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation
Huston, E., Lynch, M. J., Mohamed, A., Collins, D. M., Hill, E. V., MacLeod, R., Krause, E., Baillie, G. S., & Houslay, M. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805167105 · Cited by 129 · cited 3×
“Huston et al. (2008) demonstrated that the ability of EPAC to trigger nuclear/cytoplasmic trafficking of DNA-dependent protein kinase (DNA-PK), a critical kinase that acts to repair double-stranded breaks (DSBs) in damaged DNA and that also phosphorylates the cell survival kinase PKB/Akt in the…”
BackgroundWalker, W. S., Gatewood, J., Olivas, E., Askew, D., & Havenith, C. E. G. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00146-8 · Cited by 91 · cited 1×
“The immortalized EOC2 murine microglial cell line (CRL-2467, purchased from ATCC, Manassas, VA) was employed for these studies as they exhibit both pheno- typical and functional properties of primary microglial cells (Walker et al., 1995).”
Method
Cited by
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
“Specifically, within the CNS, activation of microglia and its associated cytokine production are primarily responsible for the inflammatory responses (Frank et al., 2007; Ghosh et al., 2012; Frontiers in Physiology | www.frontiersin.org 11 June 2020 | Volume 11 | Article 598 Zhu et al., 2019).”
BackgroundCheng, J., Liao, Y., Dong, Y., Hu, H., Yang, N., Kong, X., Li, S., Li, X., Guo, J., Qin, L., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1719723 · Cited by 233
Human Microglia Show Unique Transcriptional Changes in Alzheimer's Disease
Prater, K. E., Green, K. J., Mamde, S., Sun, W., Cochoit, A., Smith, C. L., Chiou, K. L., Heath, L., Rose, S. E., Wiley, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00424-y · Cited by 164
Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229819 · Cited by 157
“For example, this pathway is modulated in monocytes, macrophages and microglia by phosphodiesterase-4B (PDE4B) [56, 57], while treatment with a PDE4B allosteric inhibitor after acute brain injury reduces microglial activation, reduces production of TNF, and provides neuroprotective benefit in rats [58].”
BackgroundPhosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121
Metadata
- Authors
- Ghosh, M., Garcia‐Castillo, D., Aguirre, V., Golshani, R., Atkins, C. M., Bramlett, H. M., Dietrich, W. D., & Pearse, D. D.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2012-08-02
- Volume
- 60
- Issue
- 12
- Pages
- 1839-1859
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2082567364
- Cited by
- 97
- References
- 6
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.